Kuehn Law Encourages Investors of PepGen Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - September 4, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of PepGen Inc. (NASDAQ: PEPG) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at PepGen caused the company to misrepresent or fail to disclose that (i) PGN-EDO51 was less effective and safe than insiders had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. FDA approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, public statements were materially false and misleading at all relevant times.

If you currently own PEPG and purchased prior to March 7, 2024 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265150